• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by AAVantgarde

    News headline image
    AAVantgarde Completes Enrollment in LUCE-1 Phase 1/2 Clinical Trial of AAVB-081 for Usher Syndrome Type B-associated Retinitis Pigmentosa
    From AAVantgarde
    Via GlobeNewswire
    News headline image
    AAVantgarde to Present at the 44th Annual J.P. Morgan Healthcare Conference
    From AAVantgarde
    Via GlobeNewswire
    News headline image
    AAVantgarde Closes $141 Million Series B Financing to Advance its Clinical Programs in Stargardt Disease and Usher 1B Syndrome
    From AAVantgarde
    Via GlobeNewswire
    News headline image
    AAVantgarde announces 3 presentations at ESGCT 2025 annual meeting
    From AAVantgarde
    Via GlobeNewswire
    News headline image
    AAVantgarde Announces FDA Orphan Drug Designation and UK CTA approval for AAVB-039 for the Treatment of Stargardt Disease
    From AAVantgarde
    Via GlobeNewswire
    News headline image
    AAVantgarde presents updated positive clinical data from its AAVB-081 program for Usher 1B at EURetina 2025
    From AAVantgarde
    Via GlobeNewswire
    News headline image
    AAVantgarde to Present Updated Clinical Data from LUCE-1 Study at EURetina 2025
    From AAVantgarde
    Via GlobeNewswire
    News headline image
    AAVantgarde Bio Announces FDA Fast Track Designation for AAVB-039 for the Treatment of Stargardt Disease
    From AAVantgarde
    Via GlobeNewswire
    News headline image
    AAVantgarde Receives FDA Clearance to Progress Stargardt Disease Asset, AAVB-039, into CELESTE, a Phase 1/2 Clinical Trial
    From AAVantgarde
    Via GlobeNewswire
    News headline image
    AAVantgarde presents positive clinical data from its AAVB-081 program for Usher 1B and preclinical data from its AAVB-039 program for Stargardt at the ARVO 2025 annual meeting
    From AAVantgarde
    Via GlobeNewswire
    News headline image
    AAVantgarde appoints Mr. Rasmus Holm-Jorgensen as Chief Financial Officer
    From AAVantgarde
    Via GlobeNewswire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.